1 Reason to Buy Bristol Myers Squibb Stock

Core Viewpoint - Investors are increasingly interested in Bristol Myers Squibb (BMY) due to its high dividend yield of 5.5% and a consistent history of dividend growth over 25 years [1][2]. Group 1: Dividend Yield and Comparison - Bristol Myers Squibb offers a substantial dividend yield of 5.5%, significantly higher than the average yield of 1.2% for dividend-paying stocks in the S&P 500 [2]. Group 2: Patent Expirations and Revenue Impact - The company recently lost exclusivity for Revlimid, a cancer therapy that peaked at $12.8 billion in sales in 2021, and will soon lose exclusivity for Eliquis, which accounts for approximately 31% of total revenue [4]. Group 3: Growth Potential from New Treatments - Despite challenges from patent expirations, Bristol Myers Squibb has a promising growth portfolio with at least seven drugs that experienced double-digit sales growth in the second quarter, including Breyanzi, which saw sales more than double [5]. - Anticipated sales for Cobenfy, a new schizophrenia treatment approved by the FDA, are projected to reach $2.6 billion by 2030 [6]. Group 4: Earnings and Dividend Commitment - The company expects earnings per share to be between $6.35 and $6.65 this year, which exceeds the annualized dividend commitment of $2.48 per share, indicating strong financial health [7]. - With a robust lineup of new products, the high-yield dividend is expected to continue growing for at least another decade [7].